Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
11.98
Oct 20 • 3:59 PM ET Dollar change+1.49 Percentage change(14.20%)
Aftermarket Close
12.08
Aftermarket • 7:59 PM ET Dollar change+0.10 Percentage change(0.83%)
Oct 20, 8:33 PMNo clear catalyst identified; SELLAS gains 14% amid biotech rotation and retail speculation
Index
RUT
Market Cap
2.42B
Enterprise Value
2.28B
Income
-32.46M
Sales
0.00M
Book/sh
0.68
Cash/sh
0.69
Employees
13
IPO
Mar 12, 2008
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
17.57
P/C
17.48
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
18.83
Current Ratio
18.83
Debt/Eq
0.01
LT Debt/Eq
0.00
Option/Short
Yes / Yes
EPS (ttm)
-0.21
EPS next Y
-0.10
EPS next Q
-0.05
EPS this Y
18.00%
EPS next Y
53.66%
EPS next 5Y
-
EPS past 3/5Y
51.28% 34.92%
Sales past 3/5Y
- -
EPS Y/Y TTM
35.38%
Sales Y/Y TTM
-
EPS Q/Q
24.18%
Sales Q/Q
-
Insider Own
1.11%
Insider Trans
0.00%
Inst Own
36.73%
Inst Trans
11.34%
ROA
-36.54%
ROE
-39.63%
ROIC
-23.55%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
3.82%
SMA50
-3.45%
SMA200
44.47%
Trades
Shs Outstand
201.92M
Shs Float
199.70M
52W High
15.88 -24.54%
52W Low
1.39 761.87%
Volatility
11.44% 7.48%
ATR (14)
0.94
RSI (14)
51.94
Beta
2.71
Rel Volume
1.60
Avg Volume
6.43M
Volume
10,255,886
Perf Week
-3.46%
Perf Month
5.36%
Perf Quarter
-0.83%
Perf Half Y
138.17%
Perf YTD
217.77%
Perf Year
496.02%
Perf 3Y
1153.79%
Perf 5Y
32.08%
Perf 10Y
-99.87%
Prev Close
10.49
Price
11.98
Change %
14.20%
Date Action Analyst Rating Change Price Target Change
Jul-21-21Initiated Cantor Fitzgerald Overweight $18
Nov-01-18Initiated Oppenheimer Outperform
Apr-02-18Initiated H.C. Wainwright Buy $11
Mar-19-18Upgrade Maxim Group Hold → Buy $13
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kalin Katherine BachDirectorNov 19 '25Buy1.5963,400100,806104,400Nov 21 08:45 AM
SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.
ScD h.c.Dr. Angelos M. Stergiou M.D.
Senior VP & CFOMr. John Thomas Burns CPA
MBADr. Dragan Cicic M.D.
VPMs. Stacy E. Yeung
Senior VP of Regulatory AffairsMr. Andrew Elnatan